Suppr超能文献

膳食补充剂中新型掺杂剂——2-乙基氨基-1-苯基丁烷的测定及单次口服补充剂剂量后的排泄研究

Determination of designer doping agent--2-ethylamino-1-phenylbutane--in dietary supplements and excretion study following single oral supplement dose.

作者信息

Wójtowicz Marzena, Jarek Anna, Chajewska Katarzyna, Turek-Lepa Ewa, Kwiatkowska Dorota

机构信息

Institute of Sport, Department of Anti-Doping Research, Trylogii 2/16 Street, 01-982 Warsaw, Poland.

Institute of Sport, Department of Anti-Doping Research, Trylogii 2/16 Street, 01-982 Warsaw, Poland.

出版信息

J Pharm Biomed Anal. 2015 Nov 10;115:523-33. doi: 10.1016/j.jpba.2015.07.025. Epub 2015 Jul 26.

Abstract

The quantitative analysis of a new designer doping agent, 2-ethylamino-1-phenylbutane (EAPB) and its metabolite, 2-amino-1-phenylbutane (APB) in urine samples, and the determination of EAPB in dietary supplement samples, have been presented. The main purpose of the present study was to develop simple and reliable gas chromatography-mass spectrometry method (GC-MS) for excretion study following a single oral administration of dietary supplements containing EAPB. Three analytical methods for the determination of EAPB in urine and supplement samples, and APB in urine samples using the GC-MS system, have been validated. The method of the determination of EAPB in supplement samples was applied to analyze seventeen dietary supplements, CRAZE and DETONATE. Two other methods were used to determine the urinary excretion profile of EAPB and APB in the case of three healthy volunteers and, on further investigation, it was applied to the anti-doping control in sport. Quantification was obtained on the basis of the ions at m/z 86, 58 and 169, monitored for EAPB, APB and diphenylamine (used as an internal standard), respectively. The limits of detection and quantification were 2.4 and 7.3μg/g for EAPB in the case of supplement analysis, 2.9 and 8.8ng/mL for EAPB in the case of urine analysis, and 3.2 and 9.7ng/mL for APB. The other validation parameters as linearity, precision and trueness have been also investigated with the acceptable results. The extraction yield of all presented methods was above 69%. EAPB was detected in fourteen analyzed supplements (not included EAPB in their labels) and its content varied between 1.8 and 16.1mg/g. Following oral administration of three supplements with EAPB to one male and two female volunteers, the parent compound of EAPB and its metabolite were monitored and the excretion parameters as the maximum concentration of the analyte in urine (2.2-4.2μg/mL for EAPB; 1.1-5.1μg/mL for APB) and the time for the maximum height of the excretion peak (2-8h and 22h in one case for EAPB; 20-22h and 4h in one case for APB) have been indicated. EAPB and APB were detected at the level above 50ng/mL (50% of the minimum required performance level for stimulants in the anti-doping control in-competition in sport) in the urine up to 46-106h and 58-120h, respectively. Additionally, the result of the anti-doping control during swimming competition of one athlete, whose urine sample was analyzed for stimulants and narcotics, has been presented. The qualitative and quantitative analyses of new designer agents in urine samples and the excretion studies of these substances are of a great importance in the anti-doping control in sport. Moreover, the presentation of detection examples of these agents in supplements that haven't got included an information about them in the labeling, make athletes (and other supplement customers) more and more aware of the risk of the supplement use and possible health and doping consequences.

摘要

本文介绍了尿样中新型设计型兴奋剂2-乙基氨基-1-苯基丁烷(EAPB)及其代谢物2-氨基-1-苯基丁烷(APB)的定量分析,以及膳食补充剂样品中EAPB的测定。本研究的主要目的是开发一种简单可靠的气相色谱-质谱法(GC-MS),用于单次口服含EAPB的膳食补充剂后的排泄研究。已验证了三种使用GC-MS系统测定尿样和补充剂样品中EAPB以及尿样中APB的分析方法。补充剂样品中EAPB的测定方法用于分析17种膳食补充剂CRAZE和DETONATE。另外两种方法用于测定三名健康志愿者体内EAPB和APB的尿排泄情况,并在进一步研究中应用于体育反兴奋剂控制。基于分别监测EAPB、APB和二苯胺(用作内标)的质荷比为86、58和169的离子进行定量。补充剂分析中EAPB的检测限和定量限分别为2.4μg/g和7.3μg/g,尿样分析中EAPB的检测限和定量限分别为2.9ng/mL和8.8ng/mL,APB的检测限和定量限分别为3.2ng/mL和9.7ng/mL。还研究了其他验证参数,如线性、精密度和准确性,结果均可接受。所有方法的提取率均高于69%。在14种分析的补充剂(标签中未标明含EAPB)中检测到EAPB,其含量在1.8至16.1mg/g之间。给一名男性和两名女性志愿者口服三种含EAPB的补充剂后,监测了EAPB的母体化合物及其代谢物,并给出了排泄参数,如尿中分析物的最大浓度(EAPB为2.2 - 4.2μg/mL;APB为1.1 - 5.1μg/mL)以及排泄峰最大高度出现的时间(EAPB一例为2 - 8小时和22小时;APB一例为20 - 22小时和4小时)。在尿样中分别在长达46 - 106小时和58 - 120小时检测到EAPB和APB,其浓度高于50ng/mL(体育比赛中兴奋剂反兴奋剂控制所需最低性能水平的50%)。此外,还展示了一名运动员游泳比赛期间的反兴奋剂控制结果,其尿样接受了兴奋剂和麻醉品分析。尿样中新型设计型兴奋剂的定性和定量分析以及这些物质的排泄研究在体育反兴奋剂控制中具有重要意义。此外,在标签中未包含相关信息的补充剂中检测到这些兴奋剂的实例,使运动员(以及其他补充剂消费者)越来越意识到使用补充剂的风险以及可能的健康和兴奋剂后果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验